This space is reserved to celebrate the accomplishments of all postdoctoral fellows currently and formerly at MD Anderson. We invite you to let us know about important news, such as awards you received, new techniques you developed, a paper you published, or other accomplishments, like a promotion or a new job position. Our goal with this space is to develop network among postdocs.
Email us your news: firstname.lastname@example.org.
Dr. Melissa Thompson finished her postdoctoral fellowship in August 2012 at MD Anderson. After three years as the research program director for the Gulf Coast Consortia (GCC), Dr. Thompson is now associate director for the new Office of Strategic Industry Initiatives at The University of Texas Health Science Center at Houston (UTHealth). In this role, she enables collaborative relationships between UTHealth faculty and key industry partners.
Dr. Srikanth Appikonda was a postdoctoral fellow in Dr. Michelle Barton’s lab. In March 2016 Dr. Appikonda joined Ansh Labs, a biotech company based in Webster, Texas. Ansh Labs specializes in development of immunoassays for clinical diagnostics and therapeutic discoveries in the fields of reproductive health and oncofertility. As product manager, Dr. Appikonda works closely with scientists, sales and marketing staff to study, assess and identify opportunities for development of products that make a difference in biomedical research.
Dr. Clayton R. Boldt is currently a senior communications specialist in Public Relations at MD Anderson. He is responsible for developing and implementing strategic media communications programs and writing for the institution, focusing on cancer prevention-related research and activities. His work involves composing news releases, background articles, and pitch letters as well as providing media consultation for MD Anderson faculty and serving as liaison to key members of the news media. Until 2015, Dr. Boldt was an R25T Postdoctoral Fellow in Cancer Prevention, researching novel blood-based biomarkers for early ovarian cancer detection.
Dr. Lorraine R. Reitzel was a postdoctoral fellow at MD Anderson in the Health Disparities Research department. She is currently an associate professor and the associate department chair in Psychological, Health, and Learning Sciences at the University of Houston where she directs the Social Determinants / Health Disparities Laboratory (www.lorrainereitzel.com). Her research program focuses on better understanding the social determinants of health and health risk behaviors - and the specific biopsychosocial mechanisms that account for disparities in health risk behaviors and health outcomes - with an emphasis on generating highly translational results that can be used to inform policy and intervention. Much of her work is focused on addressing health disparities related to tobacco use, alone or comorbid with other substance dependence and health risk behaviors, among low socioeconomic status groups. She has published over 100 peer-reviewed empirical papers on these topics. She is currently co-leading an organizational-level policy and treatment-focused intervention to reduce tobacco use among individuals with mental and behavioral health issues. This community-engaged dissemination and implementation work with behavioral health centers across the state is supported by the Cancer Prevention and Research Institute of Texas.
Dr. Ann Bailey is currently a member of the Clinical Decision Support Team of IPCT at MD Anderson. The IPCT is a research program that has set its mission on personalizing cancer therapy for MD Anderson patients by using tumor biomarkers, namely next generation sequencing of tumor DNA, to help guide patient therapy options. Her role on this team is to assist MD Anderson clinical oncologists in interpreting tumor sequencing data and provide information on potential therapy options based on tumor genomic alterations. The information gathered on cancer genes and their implications in cancer therapy populates the publically shared content on www.personalizedcancertherapy.org. In addition, the IPCT provides this clinical support via molecular tumor boards, clinical trial planning meetings, and individual patient reports. The overall goal of the IPCT is to augment the overwhelmingly daunting task facing oncologists assessing potential therapy options of thousands of possible genomic alterations in over a hundred actionable cancer genes.
Dr. Jaymie L. Estrella was a postdoctoral fellow in Lymphoma/Myeloma. In collaboration with several industrial companies she investigated the cellular mechanisms of newly developed anti-cancer drugs using in vitro cell line models of lymphoma disease. In February 2013 she accepted a position at TEVA Pharmaceuticals as the oncology medical science liaison for the Southern California/Arizona territory. At TEVA her role is to build relations with key opinion leaders and to communicate the latest news in TEVA branded products with the oncology medical community.
Dr. Wendy Tai was an Odyssey Fellow in Experimental Pediatrics. In August 2012 she accepted a position as oncology regional medical liaison (RML) for Celgene Corporations. As a Celgene representative, her role as the TX and LA RML is to built rapport with key opinion leaders and initiate and coordinate clinical trials with the oncology research community.
Dr. Tiffany Doucette finished her postdoc in December 2011 and was promoted to instructor in Neurosurgery at MD in the laboratory of MD Anderson's Dr. Ganesh Rao.